首页> 外文会议>Computing in Cardiology Conference >ToxComp #x2214; In vitro-in vivo extrapolation system for drug proarrhythmic potency assessment
【24h】

ToxComp #x2214; In vitro-in vivo extrapolation system for drug proarrhythmic potency assessment

机译:toxcomp∔ 用于药物预训性效力评估的体外外推体系

获取原文

摘要

The project aims to develop the systems biology driven, modeling and simulation based, easy to use for non-modelers platform for the drugs proarrhythmic potency assessment at the population level. Platform realizes the in vitro-in vivo extrapolation approach thus the input data comes from the patch clamp in vitro ionic currents inhibition studies. Covariates describing variability in population include cardiomyocyte, heart and plasma physiological parameters which are correlated with basic demographic information (age, gender). Simulated output data includes action potential and ECG derivatives where APD50, APD90 and QTc are analyzed as the endpoints. System was implemented with use of the Java/JavaFX technology and is available both on line and off line and distributed under the GPLv3 license. Its main role include clinical trials optimization and waiving, helping with the go-no go decision making.
机译:该项目旨在开发基于系统的系统生物学驱动,建模和仿真,易于用于人口水平的药物预审性效力评估。 平台实现了体外的体内外推方法,因此输入数据来自膜片钳位体外离子电流抑制研究。 描述人口变异性的协变量包括心肌细胞,心脏和血浆生理参数,这些参数与基本人口统计信息(年龄,性别)相关。 模拟输出数据包括APD50,APD90和QTC作为端点分析APD50,APD90和QTC的动作电位和ECG导数。 系统使用Java / JavaFx技术实现,可在线和离线提供,并在GPLv3许可下分发。 其主要作用包括临床试验优化和放弃,帮助Go-No Go决策。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号